Biotech investor relations in europe

​In 2024 global biotech companies in Europe saw generally strong demand from European retail, sophisticated and institutional investors.

Interest was especially strong in those companies with a dual-listing on Frankfurt Stock Exchange.
Choosing the right IR partner in Europe is critical for companies looking to engage with, and nurture trust from, European investors.

Biotech investor relations (IR) is fundamentally different from IR in other industries. Unlike traditional companies valued on near-term profitability, biotech firms operate in a high-risk, long-term development cycle where value is tied to future potential rather than immediate revenue. Successfully engaging with the investment community requires a strategic, specialized approach.

We are seeing an increasing appetite from EU investors for quality global biotech and life sciences companies with a dual-listing on Frankfurt Stock Exchange.

Technology: Translating Innovation into Investor Confidence

A biotech company's technology is its most valuable asset, but early-stage biotech innovations are often unproven. A common pitfall is being too immersed in the science, making it difficult to clearly articulate your value proposition to investors.

The ability to explain your technology’s uniqueness, origins, and competitive advantage in a compelling yet accessible way is essential. While many biotech investors have scientific or medical backgrounds, your messaging must remain concise, strategic, and investment-focused.

We work with specialist biotech experts in Germany that create detailed articles in easy-to-understand language for German equity media publications.

Managing Risk: A Clear Roadmap Through Development and Regulation

Biotech investments come with inherent risks, from drug development and regulatory hurdles to commercial viability. Investors need to understand how your company plans to mitigate these risks.

A strong IR strategy requires a transparent and well-structured narrative, outlining your pathway through clinical development, regulatory approval, and market adoption. Clarity on these key milestones builds investor confidence and distinguishes your company from competitors.

Demonstrating Opportunity: Credibility and Market PotentialThe life sciences industry presents immense growth potential, but credibility is key when defining your market opportunity.

Investors expect biotech companies to provide realistic, data-backed projections of potential market size, adoption rates, and competitive positioning.

While bold projections can be persuasive, they must be defensible—your ability to justify revenue potential and peak sales estimates will directly impact how investors model your future value.

Meeting HNW/FO investors face-to-face in Europe is important. Many global companies present at EU events such as BioEurope and this also open up opportunities for an EU investor roadshow in cities such as Frankfurt, Munich or Zurich.

Financial Strategy: Planning for Capital Market Expectations

Most biotech companies rely on external funding throughout their lifecycle, requiring a proactive approach to capital markets. Investors anticipate strategic fundraising aligned with key milestones, such as positive Phase 2 or Phase 3 clinical data.

A well-structured IR strategy ensures your company is positioned for sustainable growth while meeting investor expectations for financial planning and execution.

When meeting DACH region HNW/FO investors it is important to be able to clearly articulate a company's capital requirements, strategy, cash flow management and vision.

Why the Right Investor Relations Partner Matters​

Given the complexity and unique challenges of biotech IR, choosing the right investor relations firm is crucial.

A strong European IR partner will not only help craft a compelling investment thesis for EU investors but also navigate market expectations, engage the right investors, and optimise your communications strategy.

With the right European IR strategy and support, your life sciences company can maximize European investor confidence, secure capital efficiently, and develop long-holding and engaged investors in Europe.

In Europe we collaborate with a company's home IR firm to ensure a clear and consistent message across global markets. We have deep relationships with DACH region financial journalists and article writers to nurture engagement and interest with biotech, life sciences and impact investors in Europe.
​
There are 12 million equity and ETF investors in Germany alone - this is an important market for biotech, medtech and life sciences companies to engage with.